CREB1 Regulates KPNA2 by Inhibiting Mir-495-3p Transcription to Control Melanoma Progression : The Role of the CREB1/miR-495-3p/KPNA2 Axis in Melanoma Progression

Overview

Journal BMC Mol Cell Biol

Publisher Biomed Central

Specialty Cell Biology

Date 2022 Dec 15

PMID 36522613

Authors

Xuerui Geng

Xiujuan Qiu

Jun Gao

Zhifan Gong

Xiaogang Zhou

Chunlei Liu

Haichao Luo

Affiliations

Soon will be listed here.

Abstract

Background: Melanoma is a common type of skin cancer, and its incidence is increasing gradually. Exploring melanoma pathogenesis helps to find new treatments.

Objective: We aimed to explore the potential molecular mechanisms by which CREB1 regulates melanoma.

Methods: TransmiR and ALGGEN were used to predict targets of CREB1 in the promoter of miR-495-3p or miR-495-3p and KPNA2, and a dual-luciferase reporter assay was performed to detect binding of CREB1 to these promoters. In addition, binding of CREB1 to the miR-495-3p promoter was confirmed by a ChIP assay. qRT‒PCR was carried out to detect mRNA levels of miR-495-3p, CREB1 and KPNA2. An EdU assay was conducted to detect cell viability. Transwell assays and flow cytometry were performed to assess cell migration and invasion and apoptosis, respectively. Moreover, factors associated with overall survival were analysed by using the Cox proportional hazards model.

Results: Our results show miR-495-3p to be significantly decreased in melanoma. Additionally, miR-495-3p overexpression inhibited melanoma cell viability. CREB1 targeted miR-495-3p, and CREB1 overexpression enhanced melanoma cell viability by inhibiting miR-495-3p transcription. Moreover, miR-495-3p targeted KPNA2, and CREB1 regulated KPNA2 by inhibiting miR-495-3p transcription to enhance melanoma cell viability.

Conclusion: CREB1 regulates KPNA2 by inhibiting miR-495-3p transcription to control melanoma progression. Our results indicate the molecular mechanism by which the CREB1/miR-495-3p/KPNA2 axis regulates melanoma progression.

References

Feng X . miR-548b Suppresses Melanoma Cell Growth, Migration, and Invasion by Negatively Regulating Its Target Gene HMGB1. Cancer Biother Radiopharm. 2021; 36(2):189-201. DOI: 10.1089/cbr.2019.3507. View

Zhang J, Zheng H, Li K, Zhu Y . miR-495-3p depresses cell proliferation and migration by downregulating HMGB1 in colorectal cancer. World J Surg Oncol. 2022; 20(1):101. PMC: 8966301. DOI: 10.1186/s12957-022-02500-w. View

Lange A, Mills R, Lange C, Stewart M, Devine S, Corbett A . Classical nuclear localization signals: definition, function, and interaction with importin alpha. J Biol Chem. 2006; 282(8):5101-5. PMC: 4502416. DOI: 10.1074/jbc.R600026200. View

Alshareeda A, Negm O, Green A, Nolan C, Tighe P, Albarakati N . KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. Br J Cancer. 2015; 112(12):1929-37. PMC: 4580386. DOI: 10.1038/bjc.2015.165. View

Li H, Wang D, Yi B, Cai H, Wang Y, Lou X . SUMOylation of IGF2BP2 promotes vasculogenic mimicry of glioma via regulating OIP5-AS1/miR-495-3p axis. Int J Biol Sci. 2021; 17(11):2912-2930. PMC: 8326132. DOI: 10.7150/ijbs.58035. View

Liu X, Zhang H, Zhou P, Yu Y, Zhang H, Chen L . acts via the miR‑922/ axis to enhance malignant behavior of liver cancer cells. Oncol Rep. 2021; 45(5). PMC: 8020205. DOI: 10.3892/or.2021.8030. View

Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U . Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v126-32. DOI: 10.1093/annonc/mdv297. View

Yan L, You W, Sheng N, Gong J, Hu L, Tan G . A CREB1/miR-433 reciprocal feedback loop modulates proliferation and metastasis in colorectal cancer. Aging (Albany NY). 2018; 10(12):3774-3793. PMC: 6326693. DOI: 10.18632/aging.101671. View

Duan B, Geng X, Wu Y . lncRNA RNCR2 facilitates cell proliferation and epithelial-mesenchymal transition in melanoma through HK2-mediated Warburg effect via targeting miR-495-3p. Neoplasma. 2021; 68(4):692-701. DOI: 10.4149/neo_2021_201120N1255. View

10.

Zhang Y, Zhang M, Yu F, Lu S, Sun H, Tang H . Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer. J Exp Clin Cancer Res. 2015; 34:145. PMC: 4665890. DOI: 10.1186/s13046-015-0261-3. View

11.

Davis L, Shalin S, Tackett A . Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019; 20(11):1366-1379. PMC: 6804807. DOI: 10.1080/15384047.2019.1640032. View

12.

Banesh S, Trivedi V . CD36 Ectodomain Detects Apoptosis in Mammalian Cells. Mol Biotechnol. 2021; 63(11):992-1003. DOI: 10.1007/s12033-021-00356-1. View

13.

Mkhobongo B, Chandran R, Abrahamse H . The Role of Melanoma Cell-Derived Exosomes (MTEX) and Photodynamic Therapy (PDT) within a Tumor Microenvironment. Int J Mol Sci. 2021; 22(18). PMC: 8465141. DOI: 10.3390/ijms22189726. View

14.

Zhao G, Zhang L, Qian D, Sun Y, Liu W . miR-495-3p inhibits the cell proliferation, invasion and migration of osteosarcoma by targeting C1q/TNF-related protein 3. Onco Targets Ther. 2019; 12:6133-6143. PMC: 6684487. DOI: 10.2147/OTT.S193937. View

15.

Bustos M, Ono S, Marzese D, Oyama T, Iida Y, Cheung G . MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma. J Invest Dermatol. 2017; 137(9):1955-1964. DOI: 10.1016/j.jid.2017.03.039. View

16.

Luo W, Liu L, Yang L, Dong Y, Liu T, Wei X . The vitamin D receptor regulates miR-140-5p and targets the MAPK pathway in bone development. Metabolism. 2018; 85:139-150. DOI: 10.1016/j.metabol.2018.03.018. View

17.

Zhao X, Shen F, Ma J, Zhao S, Meng L, Wang X . CREB1-induced miR-1204 promoted malignant phenotype of glioblastoma through targeting NR3C2. Cancer Cell Int. 2020; 20:111. PMC: 7137285. DOI: 10.1186/s12935-020-01176-0. View

18.

Leung S, Harreman M, Hodel M, Hodel A, Corbett A . Dissection of the karyopherin alpha nuclear localization signal (NLS)-binding groove: functional requirements for NLS binding. J Biol Chem. 2003; 278(43):41947-53. DOI: 10.1074/jbc.M307162200. View

19.

Domingues B, Lopes J, Soares P, Populo H . Melanoma treatment in review. Immunotargets Ther. 2018; 7:35-49. PMC: 5995433. DOI: 10.2147/ITT.S134842. View

20.

Sood S, Jayachandiran R, Pandey S . Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. Integr Cancer Ther. 2021; 20:1534735421990078. PMC: 8743966. DOI: 10.1177/1534735421990078. View